経皮ドラッグデリバリーデバイス：市場洞察・競合情勢・市場予測 (～2032年)

経皮ドラッグデリバリーデバイスの市場規模は、2024年の715億6,627万米ドルから、予測期間中はCAGR 6.91％で推移し、2032年には1,217億9,876万米ドルの規模に成長すると予測されています。

慢性疾患の有病率の増加と第3世代経皮ドラッグデリバリーデバイスの採用拡大が、これらのデバイスの世界市場を大幅に押し上げています。技術の進歩によりデバイスの効率が向上し、薬物吸収と患者の利便性が向上しています。また、ホルモン疾患、心血管疾患、疼痛管理など多方面への応用が可能で、非侵襲的でコントロールしやすく、患者に優しい薬物デリバリーの選択肢を提供することが、需要をさらに押し上げています。これらの要因が相まって、2025年から2032年までの予測期間中、経皮ドラッグデリバリーデバイスの使用と開発が世界中で拡大しています。

タイプ別では、薬剤含有粘着パッチの部門が2024年に55.44%をのシェアを示し、市場を独占すると推定されています。これらの粘着パッチが提供するさまざまな利点や用途が、予測期間中の需要を牽引する見通しです。薬剤含有粘着経皮パッチは、皮膚から血流に薬剤を送達するように設計されたドラッグデリバリーシステムの一種です。これらのパッチは、薬物を経時的に放出するように設計されており、制御された一貫した治療投与量を提供します。粘着層はパッチを皮膚に接着させ、また薬物の放出速度を制御するのに役立ちます。パッチが皮膚に貼付されると、薬物は徐々に皮膚から血流に拡散し、時間の経過とともに安定した制御された薬物放出が行われます。

地域別では、北米が2024年に45.39%で最大のシェアを占め、予測期間中はCAGR 5.91%で成長すると予測されています。これは、同地域における慢性疼痛、中枢神経系疾患、心血管疾患などの対象疾患の有病率の増加、新製品の発売、研究開発活動への注力の高まりなどによるものと考えられています。

当レポートでは、世界の経皮ドラッグデリバリーデバイスの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 経皮ドラッグデリバリーデバイス市場レポート：イントロダクション

• 調査範囲
• 市場セグメンテーション
• 市場の前提因子

第2章 経皮ドラッグデリバリーデバイス市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 経皮ドラッグデリバリーデバイス市場：主要要因分析

• 市場促進要因
  • 慢性疾患の増加
  • 第三世代の経皮ドラッグデリバリーデバイスの採用増加
  • 技術進歩の増加
  • 世界中でのデバイス利用の増加：ホルモン障害から心血管疾患、疼痛管理まで
• 市場抑制要因と課題
  • 経皮ドラッグデリバリーデバイスに伴う制限 (適用部位の刺激や浮腫など)
  • 製品リコールの増加
• 市場機会
  • 経皮ドラッグデリバリーデバイスに対する意識の高まり
  • 痛みのない経皮ドラッグデリバリーデバイスに対する患者の採用増加

第6章 経皮ドラッグデリバリーデバイス市場：ポーターのファイブフォース分析

第7章 経皮ドラッグデリバリーデバイス市場の評価

• タイプ別
  • 薬剤含有粘着パッチ
  • マトリックスパッチ
  • リザーバー膜パッチ
  • マイクロニードルパッチ
• 用途別
  • 疼痛管理
  • 中枢神経系疾患
  • ホルモン
  • 心血管疾患
  • その他
• エンドユーザー別
  • 病院
  • 外来手術センター
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 経皮ドラッグデリバリーデバイス市場：企業・製品プロファイル

• Novartis
• Viatris Inc.
• UCB SA
• Hisamitsu Pharmaceutical
• Boehringer Ingelheim
• Johnson & Johnson Services Inc.
• Purdue Pharma
• Bayer AG
• Haleon Group of Companies
• Ingenus Pharmaceuticals
• Luye Pharma Group
• Cumberland Pharmaceuticals Inc.
• Sanofi
• Sparsha Pharma International Pvt Ltd.
• Cipla

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Transdermal Drug Delivery Devices Market in Global (2022-2032)
• Table 3: Transdermal Drug Delivery Devices Market in Global by Type (2022-2032)
• Table 4: Transdermal Drug Delivery Devices Market in Global by Application (2022-2032)
• Table 5: Transdermal Drug Delivery Devices Market in Global by End-User (2022-2032)
• Table 6: Transdermal Drug Delivery Devices Market in Global by Geography (2022-2032)
• Table 7: Transdermal Drug Delivery Devices Market in North America (2022-2032)
• Table 8: Transdermal Drug Delivery Devices Market in the United States (2022-2032)
• Table 9: Transdermal Drug Delivery Devices Market in Canada (2022-2032)
• Table 10: Transdermal Drug Delivery Devices Market in Mexico (2022-2032)
• Table 11: Transdermal Drug Delivery Devices Market in Europe (2022-2032)
• Table 12: Transdermal Drug Delivery Devices Market in France (2022-2032)
• Table 13: Transdermal Drug Delivery Devices Market in Germany (2022-2032)
• Table 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2022-2032)
• Table 15: Transdermal Drug Delivery Devices Market in Italy (2022-2032)
• Table 16: Transdermal Drug Delivery Devices Market in Spain (2022-2032)
• Table 17: Transdermal Drug Delivery Devices Market in the Rest of Europe (2022-2032)
• Table 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2022-2032)
• Table 19: Transdermal Drug Delivery Devices Market in China (2022-2032)
• Table 20: Transdermal Drug Delivery Devices Market in Japan (2022-2032)
• Table 21: Transdermal Drug Delivery Devices Market in India (2022-2032)
• Table 22: Transdermal Drug Delivery Devices Market in Australia (2022-2032)
• Table 23: Transdermal Drug Delivery Devices Market in South Korea (2022-2032)
• Table 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2022-2032)
• Table 25: Transdermal Drug Delivery Devices Market in the Rest of the World (2022-2032)
• Table 26: Transdermal Drug Delivery Devices Market in the Middle East (2022-2032)
• Table 27: Transdermal Drug Delivery Devices Market in Africa (2022-2032)
• Table 28: Transdermal Drug Delivery Devices Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Transdermal Drug Delivery Devices Market in Global (2022-2032)
• Figure 3: Transdermal Drug Delivery Devices Market in Global by Type (2022-2032)
• Figure 4: Transdermal Drug Delivery Devices Market in Global by Application (2022-2032)
• Figure 5: Transdermal Drug Delivery Devices Market in Global by End-User (2022-2032)
• Figure 6: Transdermal Drug Delivery Devices Market in Global by Geography (2022-2032)
• Figure 7: Transdermal Drug Delivery Devices Market in North America (2022-2032)
• Figure 8: Transdermal Drug Delivery Devices Market in the United States (2022-2032)
• Figure 9: Transdermal Drug Delivery Devices Market in Canada (2022-2032)
• Figure 10: Transdermal Drug Delivery Devices Market in Mexico (2022-2032)
• Figure 11: Transdermal Drug Delivery Devices Market in Europe (2022-2032)
• Figure 12: Transdermal Drug Delivery Devices Market in France (2022-2032)
• Figure 13: Transdermal Drug Delivery Devices Market in Germany (2022-2032)
• Figure 14: Transdermal Drug Delivery Devices Market in the United Kingdom (2022-2032)
• Figure 15: Transdermal Drug Delivery Devices Market in Italy (2022-2032)
• Figure 16: Transdermal Drug Delivery Devices Market in Spain (2022-2032)
• Figure 17: Transdermal Drug Delivery Devices Market in the Rest of Europe (2022-2032)
• Figure 18: Transdermal Drug Delivery Devices Market in Asia-Pacific (2022-2032)
• Figure 19: Transdermal Drug Delivery Devices Market in China (2022-2032)
• Figure 20: Transdermal Drug Delivery Devices Market in Japan (2022-2032)
• Figure 21: Transdermal Drug Delivery Devices Market in India (2022-2032)
• Figure 22: Transdermal Drug Delivery Devices Market in Australia (2022-2032)
• Figure 23: Transdermal Drug Delivery Devices Market in South Korea (2022-2032)
• Figure 24: Transdermal Drug Delivery Devices Market in Rest of Asia-Pacific (2022-2032)
• Figure 25: Transdermal Drug Delivery Devices Market in the Rest of the World (2022-2032)
• Figure 26: Transdermal Drug Delivery Devices Market in the Middle East (2022-2032)
• Figure 27: Transdermal Drug Delivery Devices Market in Africa (2022-2032)
• Figure 28: Transdermal Drug Delivery Devices Market in South America (2022-2032)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Market Opportunities
• Figure 32: PORTER'S Five Force Analysis

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and use of these devices from hormonal disorders to cardiovascular conditions and pain management across the globe.

The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032. The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

Transdermal Drug Delivery Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases.

Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. As the prevalence of CVDs rises globally, particularly among aging populations and individuals with sedentary lifestyles, the need for convenient, long-term treatment solutions has intensified. Thus, transdermal drug delivery devices allow for controlled and consistent delivery of medications like antihypertensives, antianginal drugs, and anticoagulants, ensuring better therapeutic outcomes and improved patient compliance thereby boosting the overall market across the globe.

Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Thus, with the rising prevalence of neurological disorders, there is a growing demand for non-invasive and effective treatment methods. These transdermal drug delivery devices provide controlled and consistent delivery of medications, bypassing the gastrointestinal tract and reducing side effects often associated with oral or injectable therapies thereby boosting the market of transdermal drug delivery devices across the globe.

Additionally, the increase in strategic activities among the key market players is further boosting the market of transdermal drug delivery devices across the globe. For instance, in January 2024, Starton Therapeutics announced the launch of STARSILON a novel proprietary transdermal patch delivery platform.

Thus, the factors mentioned above are expected to boost the overall market of transdermal drug delivery devices across the globe during the forecast period from 2025 to 2032.

However, disadvantages associated with transdermal drug delivery devices such as irritation at the site of application edema and increased product recalls may hinder the future market of transdermal drug delivery devices across the globe during the forecasted period.

Transdermal Drug Delivery Devices Market Segment Analysis:

Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The drug-in-adhesive patches category in the transdermal drug delivery devices market is estimated to dominate the market with a market share of 55.44% in 2024. This can be attributed to the various advantages and applications provided by these adhesive patches which will be responsible for driving the demand for transdermal drug delivery devices market during the given forecast period. Drug-in-adhesive transdermal patches are a type of drug delivery system designed to deliver drugs through the skin and into the bloodstream. These patches are designed to release the drug over time, providing a controlled and consistent therapeutic dosage. The adhesive layer adheres the patch to the skin and also helps to control the rate at which the drug is released. When the patch is applied to the skin, the drug gradually diffuses through the skin and into the bloodstream, providing a steady and controlled release of medication over time.

Drug-in-adhesive transdermal patches are easy to apply and do not require needles or invasive procedures, making them more convenient and patient-friendly. These drug delivery systems provide a controlled and consistent release of medication over a prolonged period, which helps to maintain stable drug levels in the bloodstream. Further presence of some key products in the market such as TRANSDERM-V by Novartis and Mylan-rivastigmine Patch 10 by Viatris Inc. will also contribute in propelling the growth of this category.

Hence, owing to the above-mentioned factors, the market for drug-in-adhesive will experience increased demand, thus driving the overall transdermal drug delivery devices market during the forecast period.

North America is expected to dominate the overall transdermal drug delivery devices market:

Among all regions, North America is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032. This can be attributed to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

Additionally, as per the recent data provided by the Alzheimer's Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Furthermore, as per the recent data provided by the Parkinson's Foundation (2022), nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year and approximately one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Thus, the rising prevalence of these diseases, coupled with the demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating the adoption of transdermal technologies.

Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the spinal non-fusion devices market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG announced the launch of the UDENYCA(R) on-body injector (OBI) through its Sorrel(TM) platform. UDENYCA(R) (pegfilgrastim-cbqv) aims to reduce infection risks post-chemotherapy. The FDA approved the device in December 2023, enhancing patient convenience and drug administration at home.

Thus, the above-mentioned factors are expected to escalate the market of transdermal drug delivery devices in the region.

Transdermal Drug Delivery Devices Market Key Players:

Some of the key market players operating in the transdermal drug delivery devices market include Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

Recent Developmental Activities in the Transdermal Drug Delivery Devices Market:

• In July 2024, Kindeva Drug Delivery's Woodbury, MN facility was FDA-inspected and classified. The facility now supports clients with integrated and stand-alone analytical services for pharmaceutical, biopharmaceutical, and medical device sectors.
• In March 2024, PassPort Technologies, Inc., a San Diego-based clinical-stage company, reported positive interim results from its Phase 1 trial of Zolmitriptan PassPort(R), using a proprietary transdermal microporation system for acute migraine treatment. Zolmitriptan, an FDA-approved migraine medication, is tested for efficacy via this new delivery system.

Key Takeaways From the Transdermal Drug Delivery Devices Market Report Study

• Market size analysis for current transdermal drug delivery devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the transdermal drug delivery devices market.
• Various opportunities available for the other competitors in the transdermal drug delivery devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current transdermal drug delivery devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for transdermal drug delivery devices market growth in the coming future?

Target Audience Who Can be Benefited From This Transdermal Drug Delivery Devices Market Report Study

• Transdermal drug delivery devices product providers
• Research organizations and consulting companies
• Transdermal Drug Delivery Devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in transdermal drug delivery devices
• Various end-users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.

Frequently Asked Questions for the Transdermal Drug Delivery Devices Market:

1. What are transdermal drug delivery devices?

• Transdermal drug delivery (TDD) is a method that delivers drugs through the skin for controlled, sustained release over time. It improves patient compliance and avoids first-pass metabolism in the liver, providing an appealing alternative to oral and hypodermic drug administration.

2. What is the market for transdermal drug delivery devices?

• The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032.

3. What are the drivers for the global transdermal drug delivery devices market?

• The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global transdermal drug delivery devices market?

• Some of the key market players operating in the transdermal drug delivery devices are Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.

5. Which region has the highest share in the global transdermal drug delivery devices market?

• North America region is anticipated to dominate the overall transdermal drug delivery devices market due to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.

Table of Contents

1. Transdermal Drug Delivery Devices Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Transdermal Drug Delivery Devices Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Transdermal Drug Delivery Devices Market Key Factors Analysis

• 5.1. Transdermal Drug Delivery Devices Market Drivers
  • 5.1.1. The increasing prevalence of chronic conditions
  • 5.1.2. Increase in adoption of third-generation transdermal drug delivery devices
  • 5.1.3. Increase in the technological advancements
  • 5.1.4. Increase use of these devices for hormonal disorders to cardiovascular conditions and pain management across the globe
• 5.2. Transdermal Drug Delivery Devices Market Restraints and Challenges
  • 5.2.1. Limitation associated with transdermal drug delivery devices such as irritation at site of application and edema
  • 5.2.2. Increase product recalls
• 5.3. Transdermal Drug Delivery Devices Market Opportunities
  • 5.3.1. Increasing awareness towards transdermal drug delivery devices
  • 5.3.2. Increased patient adoption for pain-less transdermal drug delivery devices

6. Transdermal Drug Delivery Devices Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Transdermal Drug Delivery Devices Market Assessment

• 7.1. By Type
  • 7.1.1. Drug-in-adhesive Patches
  • 7.1.2. Matrix Patches
  • 7.1.3. Reservoir Membrane Patches
  • 7.1.4. Microneedle Patches
• 7.2. By Application
  • 7.2.1. Pain Management
  • 7.2.2. Central Nervous System Disorders
  • 7.2.3. Hormonal Applications
  • 7.2.4. Cardiovascular Disorders
  • 7.2.5. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Ambulatory Surgical Centers
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.1.2. Canada Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.1.3. Mexico Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2.2. Germany Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2.3. United Kingdom Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2.4. Italy Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2.5. Spain Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.2.6. Rest of Europe Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3.2. Japan Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3.3. India Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3.4. Australia Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3.5. South Korea Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.4.2. Africa Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)
    • 7.4.4.3. South America Transdermal Drug Delivery Devices Market Size in USD Million (2022-2032)

8. Transdermal Drug Delivery Devices Market Company and Product Profiles

• 8.1. Novartis
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Viatris Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. UCB SA
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Hisamitsu Pharmaceutical
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Boehringer Ingelheim
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Johnson & Johnson Services Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Purdue Pharma
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Bayer AG
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Haleon Group of Companies
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Ingenus Pharmaceuticals
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Luye Pharma Group
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Cumberland Pharmaceuticals Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Sanofi
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Sparsha Pharma International Pvt Ltd.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Cipla
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us